JP2007513968A - 哺乳動物神経細胞へのｓｉＲＮＡのデリバリー - Google Patents

哺乳動物神経細胞へのｓｉＲＮＡのデリバリー Download PDF

Info

Publication number
JP2007513968A
JP2007513968A JP2006544003A JP2006544003A JP2007513968A JP 2007513968 A JP2007513968 A JP 2007513968A JP 2006544003 A JP2006544003 A JP 2006544003A JP 2006544003 A JP2006544003 A JP 2006544003A JP 2007513968 A JP2007513968 A JP 2007513968A
Authority
JP
Japan
Prior art keywords
bdnf
sirna
hypoxia
target gene
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2006544003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007513968A5 (https=
Inventor
ゴードン エス ミッチェル
ハーマン トレイシー リー ベイカー
Original Assignee
ウイスコンシン アラムニ リサーチ ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウイスコンシン アラムニ リサーチ ファンデーション filed Critical ウイスコンシン アラムニ リサーチ ファンデーション
Publication of JP2007513968A publication Critical patent/JP2007513968A/ja
Publication of JP2007513968A5 publication Critical patent/JP2007513968A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2006544003A 2003-12-12 2004-12-10 哺乳動物神経細胞へのｓｉＲＮＡのデリバリー Abandoned JP2007513968A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52932603P 2003-12-12 2003-12-12
PCT/US2004/041339 WO2005059135A2 (en) 2003-12-12 2004-12-10 Treatment of mammals by sirna delivery into mammalian nerve cells

Publications (2)

Publication Number Publication Date
JP2007513968A true JP2007513968A (ja) 2007-05-31
JP2007513968A5 JP2007513968A5 (https=) 2008-01-31

Family

ID=34699962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006544003A Abandoned JP2007513968A (ja) 2003-12-12 2004-12-10 哺乳動物神経細胞へのｓｉＲＮＡのデリバリー

Country Status (5)

Country Link
US (2) US20050234000A1 (https=)
EP (1) EP1708756A2 (https=)
JP (1) JP2007513968A (https=)
CA (1) CA2548972A1 (https=)
WO (1) WO2005059135A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011501657A (ja) * 2007-10-05 2011-01-13 サントル ナショナル ドゥ ラ ルシェルシュ スィヤンティフィック（セーエヌエルエス） 呼吸器系疾患の治療に使用することができる化合物をスクリーニングする方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2553261C (en) 2004-01-16 2014-03-18 Stefan Barth Immunokinases
MX2007002423A (es) * 2004-08-31 2007-08-07 Sylentis Sau Metodos y composiciones para inhibir la expresion del receptor p2x7.
WO2006042396A1 (en) * 2004-10-22 2006-04-27 Universite Laval Modulation of neuroglia-derived bdnf in the treatment and prevention of pain
EP1800695A1 (en) 2005-12-21 2007-06-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immuno-RNA-constructs
US8530436B2 (en) * 2007-01-29 2013-09-10 Transderm, Inc. Methods and compositions for transdermal delivery of nucleotides
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
EP2132309A4 (en) * 2007-02-23 2011-01-05 Univ Florida COMPOSITIONS AND METHODS OF TREATING GLYCOLOGICAL MEMORY DISEASES
US9265843B2 (en) 2008-03-27 2016-02-23 The Ohio State University Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor
WO2010051532A1 (en) * 2008-10-31 2010-05-06 University Of Chicago Compositions and methods related to obstructive sleep apnea
CA2756670A1 (en) * 2009-03-26 2010-09-30 The Regents Of The University Of California Mesenchymal stem cells producing inhibitory rna for disease modification
WO2012142622A1 (en) * 2011-04-15 2012-10-18 Molecular Transfer, Inc. Agents for improved delivery of nucleic acids to eukaryotic cells
KR20150020250A (ko) 2012-06-19 2015-02-25 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 당뇨병을 치료하기 위한 조성물 및 방법
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
CN116942825A (zh) * 2023-07-21 2023-10-27 南通大学 Cda基因在制备治疗神经轴突损伤相关疾病药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265387B1 (en) * 1995-10-11 2001-07-24 Mirus, Inc. Process of delivering naked DNA into a hepatocyte via bile duct
EP0969875B1 (en) * 1997-01-17 2008-11-26 Aventis Pharma S.A. Naked dna-mediated gene transfer into medullary motor neurons
CA2429814C (en) * 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011501657A (ja) * 2007-10-05 2011-01-13 サントル ナショナル ドゥ ラ ルシェルシュ スィヤンティフィック（セーエヌエルエス） 呼吸器系疾患の治療に使用することができる化合物をスクリーニングする方法

Also Published As

Publication number Publication date
US20090186844A1 (en) 2009-07-23
WO2005059135A2 (en) 2005-06-30
US20050234000A1 (en) 2005-10-20
WO2005059135A3 (en) 2005-08-18
CA2548972A1 (en) 2005-06-30
EP1708756A2 (en) 2006-10-11

Similar Documents

Publication Publication Date Title
US20090186844A1 (en) SiRNA DELIVERY INTO MAMMALIAN NERVE CELLS
Baker-Herman et al. BDNF is necessary and sufficient for spinal respiratory plasticity following intermittent hypoxia
Li et al. MiR-30b-5p attenuates oxaliplatin-induced peripheral neuropathic pain through the voltage-gated sodium channel Nav1. 6 in rats
JP2010500025A (ja) 霊長類ハンチントン遺伝子発現をｉｎｖｉｖｏで抑制する方法および配列
CN106715695A (zh) 用于治疗和诊断5‑羟色胺‑、肾上腺素‑、去甲肾上腺素‑、谷氨酸‑和促肾上腺皮质素释放激素‑相关医学病况的微rna和包含所述微rna的组合物
JP6791877B2 (ja) デュシェンヌ型筋ジストロフィーを治療するためのダイナミン２阻害剤
JP2025114630A (ja) 遺伝性ニューロパチーおよび関連障害の処置および検出
US7902166B2 (en) Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same
Litke et al. Organic anion transporter 1 is an HDAC4-regulated mediator of nociceptive hypersensitivity in mice
Barakat et al. Astroglial NF‐κB mediates oxidative stress by regulation of NADPH oxidase in a model of retinal ischemia reperfusion injury
Zhang et al. Wnt1/β-catenin signaling upregulates spinal VGLUT2 expression to control neuropathic pain in mice
JP2007530029A (ja) アネキシンｉｉ及びその使用
Guo et al. MicroRNA-133b-3p targets purinergic P2X4 receptor to regulate central poststroke pain in rats
Liu et al. Phosphorylation of the AMPARs regulated by protein kinase C (PKC) and protein interacting with C-kinase 1 (PICK1) contribute to orofacial neuropathic pain
WO2018205927A1 (zh) 钾离子通道抑制剂治疗抑郁症的用途和药物组合物
US20090258929A1 (en) Compositions and Methods for Modulating mTOR Signaling
Yang et al. Spinal sirtuin 2 attenuates bone cancer pain by deacetylating FoxO3a
US20080249038A1 (en) Bone Morphogenetic Protein (Bmp) 2A and Uses Thereof
US20220098592A1 (en) Double stranded rna and uses thereof
WO2016181011A1 (es) Método para promover la regeneración muscular
EP2317995B1 (en) Inhbitors of mrp4 and agents stimulating mrp4 activity for the treatment of cardiac disorders
Andreou Glutamate in migraine neurobiology and treatment
Zhang et al. Selective downregulation of vesicular glutamate transporter2 in ventral posterolateral nucleus of thalamus attenuates neuropathic mechanical allodynia in mice
Xia et al. E3 ligase Nedd4L promotes macrophage M1 polarization and exacerbates brain damage by TRAF3/TBK1 signaling pathway after ICH in mice
Anamthathmakula et al. Evidence suggesting phosphodiesterase-3B regulation of NPY/AgRP gene expression in mHypoE-46 hypothalamic neurons

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071210

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20081218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081218